Main menu

CyclomicsSeq: targeted and genome-wide detection of circulating tumor DNA using nanopore consensus sequencing

Get startedSubscribe
Return to Resources

Wigard Kloosterman, Cyclomics, demonstrated how CyclomicsSeq can facilitate the detection of mutations with a frequency of at least 0.02% in cfDNA in blood. He also discussed its potential for minimally-invasive presymptomatic screening in the future.

Authors: Wigard Kloosterman
Cancer Research Symposium
  • Published on: April 6 2022

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

联系我们

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

关于 Oxford Nanopore

Contact us 领导团队 媒体资源和联系方式 投资者 在 Oxford Nanopore 工作 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust

沪ICP备20017565号 © 2008 - 2023 Oxford Nanopore Technologies plc。版权所有。注册办公室：Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK（英国）{'|'} 注册号 05386273 {'|'} 增值税号 336942382。Oxford Nanopore Technologies、风轮图标、EPI2ME、Flongle、GridION、Metrichor、MinION、MinIT、MinKNOW、Plongle、 PromethION、SmidgION、Ubik 和 VolTRAX 是 Oxford Nanopore Technologies plc 在 不同国家的注册商标。Oxford Nanopore Technologies 产品并非旨在用于健康评估或 诊断、治疗、缓解、治愈或预防任何疾病或状况。

Chinese flag